Apolipoprotein (apo) C-III gene polymorphisms have been associated with increased plasma triglycerides (TGs) and coronary artery disease, but the results have not always been concordant among diverse populations. The present study was undertaken to detect the association of the apoC-III 3238C>G polymorphism and several environmental factors with serum lipid profiles in the Guangxi Hei Yi Zhuang and Han populations.
Methods
A total of 490 subjects of Hei Yi Zhuang and 540 participants of Han Chinese aged 15 to 89 years were randomly selected from our previous stratified randomized cluster samples. Genotyping of the apoC-III 3238C>G was performed by polymerase chain reaction and restriction fragment length polymorphism combined with gel electrophoresis and then confirmed by direct sequencing.
Results
There was no difference in the genotype and allele frequencies between the 2 ethnic groups (P > 0.05), but G allele and GG genotype frequencies were higher in females than in males, or in high TG than in normal TG individuals in Hei Yi Zhuang (P < 0.01); and in high total cholesterol than in normal total cholesterol subgroups, in high low-density lipoprotein cholesterol (LDL-C) than in normal LDL-C subgroups, or in high apoB than in normal apoB subgroups in Han (P < 0.05). There were also differences in the genotypic frequencies between normal apoA-I and low apoA-I subjects in Hei Yi Zhuang, and between males and females or between normal TG and high TG subgroups in Han (P < 0.05). Serum TG and apoA-I levels were correlated with genotype or allele in Hei Yi Zhuang, and TG, LDL-C, and apoB levels were associated with genotype in Han (P < 0.05). Serum lipid parameters were also correlated with age, sex, alcohol consumption, cigarette smoking, blood pressure, body weight, and body mass index.
Conclusions
There were no significant differences in genotypic and allelic frequencies between the Hei Yi Zhuang and Han populations. But the 3238G carriers have unfavorable serum lipid profiles. The differences in the serum lipid profiles between the 2 ethnic groups might result from different gene-environmental interactions.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
2.
SatohH, NishinoT, TomitaK, . Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men: results from a 10-year cohort study. Circ J. 2006;70:227–231.
3.
MärzW, ScharnaglH, WinklerK, . Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2004;110:3068–3074.
4.
KwiterovichPOJr, CoreshJ, SmithHH, . Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 1992;69:1015–1021.
5.
BodenWE.. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trail. Am J Cardiol. 2000;86:19L–22L.
6.
WuLL.Review of risk factors for cardiovascular diseases. Ann Clin Lab Sci. 1999;29:127–133.
7.
HellerDA, de FaireU, PedersenNL, . Genetic and environmental influences on serum lipid levels in twins. N Engl J Med. 1993;328:1150–1156.
8.
WangC, McConathyWJ, KloerHU, . Modulation of lipoprotein lipase activity by apolipoproteins. J Clin Invest. 1985;75:384–390.
9.
LeNA, GibsonJC, GinsbergHN.. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988;29:669–677.
10.
ItoY, AzrolanN, O'ConnellA, . Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990;249:790–793.
11.
BrunsGA, KaranthasisSK, BreslowJL.Human apolipoprotein AI-CIII gene complex is located on chromosome 11. Arteriosclerosis. 1984;4:97–102.
HegeleRA, ConnellyPW, HanleyAJ, . Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol. 1997;17:2753–2758.
14.
OrdovasJM, CiveiraF, GenestJJr, . Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 1991;87:75–86.
15.
ReesA, StocksJ, PaulH, . Haplotypes identified by DNA polymorphisms at the apolipoprotein A-1 and C-III loci and hypertriglyceridaemia. A study in a Japanese population. Hum Genet. 1986;72:168–171.
16.
HongSH, ParkWH, LeeCC, . Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem. 1997;43:13–17.
17.
FerrellRE, KambohMI, MajumderPP, . Genetic studies of human apolipoproteins. XIII. Quantitative polymorphism of apolipoprotein C-III in the Mayans of the Yucatan Peninsula. Hum Hered. 1990;40:127–135.
18.
DallongevilleJ, MeirhaegheA, CottelD, . Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis. 2000;150:149–157.
19.
WuJH, KaoJT, WenMS, . DNA polymorphisms at the apolipoprotein A1-CIII loci in Taiwanese: correlation of plasma APOCIII with triglyceride level and body mass index. J Formos Med Assoc. 2000;99:367–374.
20.
WaterworthDM, TalmudPJ, BujacSR, . Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol. 2000;20:2663–2669.
21.
WaterworthDM, TalmudPJ, HumphriesSE, . Variable effects of the APOC3-482C > T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia. 2001;44:245–248.
22.
BuzzaM, FrippY, MitchellRJ.Apolipoprotein AI. and CIII gene polymorphisms and their association with lipid levels in Italian, Greek and Anglo-Irish populations of Australia. Ann Hum Biol. 2001;28:481–490.
23.
CorellaD, GuillénM, SáizC, . Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. J Lipid Res. 2002;43:416–427.
24.
ChhabraS, NarangR, KrishnanLR, . Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet. 2002;3:9.
25.
RodrigoE, González-LamuñoD, RuizJC, . Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. Am J Transplant. 2002;2:343–348.
26.
MinihaneAM, FinneganYE, TalmudP, . Influence of the APOC3 -2854T>G polymorphism on plasma lipid levels: effect of age and gender. Biochim Biophys Acta. 2002;1583:311–314.
27.
HumphriesSE, BerglundL, IsasiCR, . Loci for CETP, LPL, LIPC, and APOC3 affect plasma lipoprotein size and sub-population distribution in Hispanic and non-Hispanic white subjects: the Columbia University Biomarkers Study. Nutr Metab Cardiovasc Dis. 2002;12:163–172.
28.
CouillardC, VohlMC, EngertJC, . Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men. J Lipid Res. 2003;44:986–993.
29.
Espino-MontoroA, Barrios-ArtilloM, López-ChozasJM, . Influence of polymorphism (RFLP-SstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism. Nutr Metab Cardiovasc Dis. 2003;13:194–201.
30.
SurguchovAP, PageGP, SmithL, . Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:941–947.
31.
LiGP, WangJY, YanSK, . Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population. Clin Genet. 2004;65:470–476.
32.
GarencC, AubertS, LarocheJ, . Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians. J Hum Genet. 2004;49:691–700.
33.
GuettierJM, GeorgopoulosA, TsaiMY, . Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab. 2005;90:1705–1711.
34.
GarencC, CouillardC, LaflammeN, . Effect of the APOC3 SstI SNP on fasting triglyceride levels in men heterozygous for the LPL P207L deficiency. Eur J Hum Genet. 2005;13:1159–1165.
35.
Ruiz-NarváezEA, YangY, NakanishiY, . APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res. 2005;46:2605–2613.
36.
HerronKL, LofgrenIE, AdiconisX, . Associations between plasma lipid parameters and APOC3 and APOA4 genotypes in a healthy population are independent of dietary cholesterol intake. Atherosclerosis. 2006;184:113–120.
37.
HuangMC, WangTN, LiuYL, . Effect of SstI polymorphism of the apolipoprotein CIII gene and environmental factors on risks of hypertriglyceridemia in Taiwan aborigines. Circ J. 2006;70:1030–1036.
38.
HallmanDM, SrinivasanSR, ChenW, . Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism. 2006;55:1574–1581.
39.
DorfmeisterB, CooperJA, StephensJW, . The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes. Biochim Biophys Acta. 2007;1772:355–363.
40.
FiegenbaumM, de AndradeFM, HutzMH.. Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes. Clin Chim Acta. 2007;380:175–181.
41.
MillerM, RhyneJ, ChenH, . APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res. 2007;38:444–451.
42.
PollexRL, BanMR, YoungTK, . Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. BMC Med Genet. 2007;8:80.
43.
ChienKL, FangWH, WenHC, . APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese. Clin Chim Acta. 2008;390:56–62.
44.
BonnetE, BernardJ, FauvelJ, . Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses. 2008;24:169–171.
45.
LahiryP, BanMR, PollexRL, . Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders. Int J Circumpolar Health. 2007;66:390–400.
46.
ParzianelloL, OliveiraG, CoelhoJC.Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in Southern Brazil. Braz J Med Biol Res. 2008;41:462–467.
RuizJR, LabayenI, OrtegaFB, . AVENA Study Group. Birth weight and blood lipid levels in Spanish adolescents: influence of selected APOE, APOC3 and PPARgamma2 gene polymorphisms. The AVENA Study. BMC Med Genet. 2008;9:98.
ZhangQ, LiuY, LiuBW, . Common genetic variants of lipoprotein lipase and apolipoproteins AI-CIII that relate to coronary artery disease: a study in Chinese and European subjects. Mol Genet Metab. 1998;64:177–183.
51.
RussoGT, MeigsJB, CupplesLA, . Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis. 2001;158:173–181.
52.
OlivieriO, StranieriC, BassiA, . ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res. 2002;43:1450–1457.
53.
BaroniMG, BerniA, RomeoS, . Genetic study of common variants at the apo E, apo AI, apo CIII, apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Med Genet. 2003;4:8.
54.
ChhabraS, NarangR, LakshmyR, . Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD. Mol Cell Biochem. 2004;259:59–66.
55.
PayseurBA, ClarkAG, HixsonJ, . Contrasting multi-site genotypic distributions among discordant quantitative phenotypes: the APOA1/C3/A4/A5 gene cluster and cardiovascular disease risk factors. Genet Epidemiol. 2006;30:508–518.
56.
MuendleinA, SaelyCH, MarteT, . Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease. Atherosclerosis. 2008;199:179–186.
57.
Ruiz-NarváezEA, SacksFM, CamposH.Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. Am J Clin Nutr. 2008;87:1932–1938.
58.
ShankerJ, PerumalG, RaoVS, . Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease. Lipids Health Dis. 2008;7:33.
59.
MarcilM, BoucherB, GagnéE, . Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. J Lipid Res. 1996;37:309–319.
60.
KeeF, AmouyelP, FumeronF, . Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study. Atherosclerosis. 1999;145:187–195.
61.
ThuNN, MaiTT, OhmoriR, . Plasma triglyceride and HDL-cholesterol concentrations in Vietnamese girls are affected by lipoprotein lipase, but not apolipoprotein CIII polymorphism. J Nutr. 2006;136:1488–1492.
62.
NieminenT, KähönenM, IslamS, . Apolipoprotein A-I/C-III/A-IV SstI and apolipoprotein B XbaI polymorphisms do not affect early functional and structural changes in atherosclerosis: the Cardiovascular Risk in Young Finns study. Circ J. 2007;71:741–745.
63.
RuixingY, YumingC, ShanglingP, . Effects of demographic, dietary and other lifestyle factors on the prevalence of hyperlipidemia in Guangxi Hei Yi Zhuang and Han populations. Eur J Cardiovasc Prev Rehabil. 2006;13:977–984.
64.
RuixingY, LimeiY, YumingC, . Prevalence, awareness, treatment, control and risk factors of hypertension in the Guangxi Hei Yi Zhuang and Han populations. Hypertens Res. 2006;29:423–432.
65.
KoYL, KoYS, WuSM, . Interaction between obesity and genetic polymorphisms in the apolipoprotein CIII gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. Hum Genet. 1997;100:327–333.
66.
BaiH, SakuK, LiuR, . Association between coronary heart disease and the apolipoprotein A-I/C-III/A-IV complex in a Japanese population. Hum Genet. 1995;95:102–104.
67.
HumphriesS, TalmudP, MonsalveV, . RFLP studies in different ethnic groups. Atherosclerosis. 1989;75:249–250.
68.
DammermanM, SandkuijlLA, HalaasJL, . An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA. 1993;90:4562–4566.
